Donanemab (LY3002813)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Donanemab (LY3002813), covering 2025-11-14 to 2025-11-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) [Phase 3]